Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/51647
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTuangrat Phodhaen_US
dc.contributor.authorArthorn Riewpaiboonen_US
dc.contributor.authorKumthorn Malathumen_US
dc.contributor.authorPeter C. Coyteen_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-01-27T09:49:56Z-
dc.date.available2020-01-27T09:49:56Z-
dc.date.issued2019-05-04en_US
dc.identifier.citationExpert Review of Pharmacoeconomics and Outcomes Research. Vol.19, No.3 (2019), 305-312en_US
dc.identifier.issn17448379en_US
dc.identifier.issn14737167en_US
dc.identifier.other2-s2.0-85055588266en_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/51647-
dc.description.abstract© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background–Antimicrobial resistance (AMR) is a major health threat worldwide as it brings about poorer outcomes and places economic burdens to society. This study aims to estimate the economic burdens from nosocomial infections (NI) caused by multi-drug resistant (MDR) bacteria in Thailand. Research design and methods–A retrospective cohort study was conducted at a tertiary hospital over 2011–2012. A multivariate log-linear regression model was used to estimate the excess treatment costs of AMR to those non-AMR patients. Results–Switching from a non-AMR case to an AMR infection case, resulted in 42% increase in expected average treatment costs per patient. The annual treatment from hospital perspective and antibiotic costs associated with the management of AMR infections were estimated to be US$ 2.3 billion and US$ 262 million, respectively. The estimated annual benefit from eradicating AMR NI were US$ 4.2 billion from a societal perspective with the annual gains in quality-adjusted life years (QALYs) of 0.6 million due to the absence of 111,295 AMR cases each year. Conclusions–Large amount of money was spent on treatment and antibiotic costs to manage AMR infections. Benefit of eliminating these infections was estimated and it would be highly cost-effective.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055588266&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleExcess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailanden_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1080/14737167.2019.1537123en_US
dc.identifier.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055588266&origin=inwarden_US
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.